论文部分内容阅读
目的比较阿托伐他汀与血脂康胶囊对含克力芝抗病毒治疗方案引起的高脂血症的疗效,探讨此类高脂血症的治疗方法。方法将60例使用含克力芝抗病毒治疗方案引起高脂血症的患者,随机分为观察组和对照组,每组各30例。观察组给予阿托伐他汀治疗,对照组给予血脂康胶囊治疗。治疗24周后比较两组的总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)的水平。结果观察组降血脂的总有效率为93.3%(28/30),高于对照组的46.7%(14/30),差异有统计学意义(P<0.05)。24周疗程结束后,2组血清TC、TG、LDL-C水平均低于治疗前,HDL-C高于治疗前,且观察组优于对照组,差异有统计学意义(P<0.05)。结论与血脂康胶囊相比,在抗病毒治疗中使用阿托伐他汀可更为有效地控制由克力芝抗病毒治疗方案引起的高脂血症,值得临床推广使用。
Objective To compare the curative effect of atorvastatin and Xuezhikang on hyperlipidemia caused by kelivirus antiviral treatment regimen and to explore the treatment of such hyperlipidemia. Methods Sixty cases of patients with hyperlipidemia who were treated with Creutzfeldt-Jakob disease were randomly divided into observation group and control group, with 30 cases in each group. The observation group was given atorvastatin, while the control group was given Xuezhikang capsule. After 24 weeks of treatment, the levels of total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL-C) and low density lipoprotein (LDL-C) were compared between the two groups. Results The total effective rate of lowering blood lipid in observation group was 93.3% (28/30), which was higher than that in control group (46.7%, 14/30), the difference was statistically significant (P <0.05). The levels of TC, TG and LDL-C in the two groups were all lower than those before treatment after 24 weeks of treatment, HDL-C was higher than that before treatment, and the observation group was better than the control group. The difference was statistically significant (P <0.05). Conclusion Compared with Xuezhikang capsule, atorvastatin can be more effective in controlling hyperlipidemia caused by Krelichvirus treatment in anti-virus therapy, which deserves clinical application.